IceCure Medical (ICCM) Cash from Financing Activities (2020 - 2026)

IceCure Medical (ICCM) has 7 years of Cash from Financing Activities data on file, last reported at $3.5 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $3.5 million, up 38.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.8 million (up 88.61% YoY), and the FY2025 annual result was $15.8 million, up 72.35% from the prior year.
• Cash from Financing Activities declined to $3.5 million in Q1 2026 per ICCM's latest filing, from $3.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $13.6 million in Q4 2022 and troughed at $68000.0 in Q4 2023.
• A 5-year average of $3.8 million and a median of $2.8 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities sank 99.5% in 2023, then jumped 1519.12% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $13.6 million in 2022, then slumped by 99.5% to $68000.0 in 2023, then jumped by 1519.12% to $1.1 million in 2024, then soared by 237.87% to $3.7 million in 2025, then decreased by 4.92% to $3.5 million in 2026.
• Business Quant data shows ICCM's Cash from Financing Activities at $3.5 million in Q1 2026, $3.7 million in Q4 2025, and $7.5 million in Q3 2025.